Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2009

NKTT Gains Access to BioWa's Platform for Use in Antibody R&D

  • NKT Therapeutics (NKTT) is tapping into BioWa's Potelligent® Technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. NKTT will use this platform to research and develop antibodies targeting natural killer T cells. BioWa will receive an up-front payment, development milestone payments, and royalties on products.

    Potelligent reportedly improves potency and efficacy of antibody therapeutics by enhancing ADCC. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »